Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone MD-Lotion in Hypogonadal Men
NCT00702650Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2008
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of Testosterone TEPI patch in Hypogonadism, sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants With 24-Hour Average Concentration [Cavg(0-24h)] Total Testosterone Within Normal Range at Day 120. Started Jun 2008; status: completed.
02
Drugs
Testosterone TEPI patch
03
Conditions
Hypogonadism
Beyond the preview
Go deeper on NCT00702650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00702650.